Medical Patent News

RSS

Viral Genetics issued patent for novel cancer therapies

Biotechnology firm Viral Genetics, Inc. has been issued a patent for novel cancer therapies. The patent protects cancer drugs that have been tested in pre-clinical research studies in mice. Issued on March 31, 2009, the U.S. Patent Number is: 7,510,710. Additional patents directed at generic classes of the drugs are still pending.

22 May 2009

AstraZeneca granted preliminary injunction against Apotex in Pulmicort Respules patent litigation

On May 20, 2009, the US District Court for the District of New Jersey granted the request of AstraZeneca for an injunction barring Apotex (Apotex, Inc. and Apotex Corp.) from launching a generic version of AstraZeneca's Pulmicort Respules (budesonide inhalation suspension) in the US. No trial date for the patent litigation has been set.

20 May 2009

Resverlogix files two patents on compounds for inflammatory diseases

Resverlogix Corp. has announced today that it has made significant advancement in the Company's research and development (R&D) program for inflammatory diseases.

19 May 2009

Atherotech receives patent for ApoB measurement for determining heart disease risk

Atherotech, Inc., developer of the VAP Cholesterol Test, has announced it has received a patent on its method to derive and report apolipoprotein B100 (apoB) using the Vertical Auto Profile (VAP) technology. The patent recognizes the unique ability of the VAP Cholesterol Test to accurately report apoB, the next milestone in heart disease risk assessment.

19 May 2009

Intradigm issued RNA interference (RNAi) patent covering potent siRNA sequence

Intradigm Corporation has announced the issuance of United States patent 7,534,878, titled "Composition and Methods of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases."

19 May 2009

U.S. Patent Office upholds StemCells’ patents

StemCells, Inc. has announced that the U.S. Patent and Trademark Office (PTO) has upheld the validity of the remaining two neural stem cell patents which were subjected to reexamination proceedings commenced by Neuralstem, Inc.

17 May 2009

American Civil Liberties Union challenges breast cancer gene patents

The American Civil Liberties Union and the Public Patent Foundation at Benjamin N. Cardozo School of Law (PUBPAT) filed a lawsuit today charging that patents on two human genes associated with breast and ovarian cancer stifle research that could lead to cures and limit women's options regarding their medical care.

12 May 2009

Wistar Institute obtains U.S. patent for a novel synthetic vaccine technology

The Wistar Institute today obtained a U.S. patent for a novel synthetic vaccine technology with the potential for further development into a universal flu vaccine which could eliminate the need for annual flu shots and protect against future flu pandemics.

6 May 2009

Acclarent granted key patent covering balloon sinuplasty technologies

Acclarent, Inc. announced today that the U.S. Patent and Trademark Office awarded U.S. Patent Number 7,500,971, entitled "Devices, Systems and Methods for Treating Disorders of the Ear, Nose and Throat," to the company.

4 May 2009

Sinobiopharma secures rights to seven key patents

Sinobiopharma Inc. has announced that it has secured rights to seven key patents from Company CEO Dr. Lequn Huang and the patents' co-holders.

27 Apr 2009

Amnis receives patent for blood and cell analysis using an imaging flow cytometer

Amnis Corporation, a manufacturer of advanced cell imaging systems, announced today that it has received U.S. patent 7,522,758.

20 Apr 2009

Star Scientific reports on patent application for Zero-Nitrosamine tobacco curing process

Star Scientific and its wholly-owned subsidiary, Rock Creek Pharmaceuticals ("Rock Creek"), have reported on their continuing efforts to lessen the harm linked with tobacco use.

16 Apr 2009

Court grants AstraZeneca temporary restraining order against Apotex in PULMICORT RESPULES patent litigation

On 16 April 2009, the US District Court for the District of New Jersey granted AstraZeneca's request for a temporary restraining order, barring Apotex (Apotex, Inc. and Apotex Corp.) from launching a generic version of AstraZeneca's PULMICORT RESPULES until further order of the court.

16 Apr 2009

Rib-X granted patent for novel oxazolidinone in China

Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced the issuance of a key antibiotic patent in China.

15 Apr 2009

Mylan confirms first-to-file patent challenge relating to Xeloda

Mylan Inc. has confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Hoffmann-La Roche Inc. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Capecitabine Tablets, 150 mg and 500 mg, the generic version of Xeloda Tablets, a chemotherapy treatment for breast and colorectal cancer.

14 Apr 2009

Optimer Pharmaceuticals receives production patent for Fidaxomicin

Optimer Pharmaceuticals, Inc. has announced that the United States Patent and Trademark Office issued a production patent (U.S. Patent No. 7,507,564) covering steps used in the manufacture of fidaxomicin, which is currently in its second Phase 3 clinical trial for the treatment of Clostridium difficile infection, or CDI.

13 Apr 2009